about
The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understandingAlzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plansAlzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes.Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans.The relative efficiency of time-to-threshold and rate of change in longitudinal dataDiagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's diseaseThe preclinical Alzheimer cognitive composite: measuring amyloid-related declineBiomarkers and cognitive endpoints to optimize trials in Alzheimer's disease.A randomized, triple-masked, active-controlled investigation of the relative effects of dose, concentration, and infusion rate for continuous popliteal-sciatic nerve blocks in volunteersAssociation of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans.Conditional Akaike information under generalized linear and proportional hazards mixed models.Developing dementia prevention trials: baseline report of the Home-Based Assessment study.Cross-validation of optimized composites for preclinical Alzheimer's disease.Parental ability to discriminate the weight status of children: results of a survey.Bayesian latent time joint mixed effect models for multicohort longitudinal data.Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials.Initiation of symptomatic medication in Alzheimer's disease clinical trials: Hypothetical versus treatment policy approach
P50
Q26801640-0C31B69B-AE33-4D5C-8F4B-7740396C14ABQ26801657-5B07EB9A-B160-44EA-9CE1-99BFB78E077FQ33601338-8A0D852F-0E15-4BA4-833E-B97EA6393A6DQ33842492-A3A21A2F-A808-41B2-A155-E7D106507974Q33842520-7A945B54-B755-4C97-9964-BC2E7C1EFABCQ33893531-FA4EF628-EDD8-4127-A8D6-1D9CDE4E98F9Q34286393-E6FC97A6-B4A9-4C9A-B844-4008A2E602A7Q34422469-038D6F06-0953-4379-875A-D2949164A440Q34477459-B73CE8BF-8A71-4805-8232-49F1DB992673Q34677434-F4ABAF66-7FE1-474B-B4B5-2797130C1104Q35844926-25355523-58EF-4B5C-9739-F1734ABED0B4Q36061970-93EA2270-B28A-45A5-A801-AE0DDE8BA3EBQ37619198-CD5B716E-B3FD-4BBA-A37F-29117CAEED06Q38373065-12DE6755-2D53-408F-AFDE-7EFCCA03E8FFQ43526187-9810917C-5F10-492F-AC7B-84C90C4BC9DDQ46674837-2937F404-CBC4-4C60-85CC-68444A326193Q53317535-83627869-0A4C-483F-94CA-A7DCC893F2D9Q91750306-F7FC4AA2-9BB3-41E4-ACF3-A1AF9622C45B
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Michael Donohue
@ast
Michael Donohue
@en
Michael Donohue
@es
Michael Donohue
@nl
Michael Donohue
@sl
type
label
Michael Donohue
@ast
Michael Donohue
@en
Michael Donohue
@es
Michael Donohue
@nl
Michael Donohue
@sl
altLabel
Mike
@en
prefLabel
Michael Donohue
@ast
Michael Donohue
@en
Michael Donohue
@es
Michael Donohue
@nl
Michael Donohue
@sl
P106
P21
P2798
P31
P496
0000-0001-6026-2238